*Note: “net profit” stands for net profit attributable to equity holders of the Company

(30 October, 2015 – Hong Kong) On 30 October 2015, Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (“Fosun Pharma” or the “Company”; stock code: 600196-SH, 02196-HK), a leading healthcare company in the People’s Republic of China, announces its financial results for the first three quarters ended 30 September 2015.

In the first three quarters of 2015, the Company recorded operating revenue of RMB9.073 billion, representing an increase of 4.76% year on year; net profit attributable to equity holders of the Company was RMB1.891 billion, representing an increase of 20.09% year on year; net profit attributable to equity holders of the Company after deduction of non-recurring profit or loss was RMB1.309 billion, representing an increase of 24.55% year on year.

The Company has proactively optimized its business and product structure, and continually strengthened its core competitiveness. In respect of pharmaceutical manufacturing and R&D, the core products of the Company achieved outstanding sales performance in the first three quarters of this year. In respect of medical service sector, the Company has accelerated the business deployment of United Family Hospital in developed cities, and devoted to rapidly expanding the operation scale of its medical service business.

Management team of the Company expressed that, the Company will still adhere to the strategy of “organic growth with external expansion and integrated business operation” in the stage of rapid development, focus on medical and healthcare businesses, incessantly improve the capability of innovation and management, and expand business in medical service industry.